Histologic validation of auto-contoured dominant intraprostatic lesions on [18F] DCFPyL PSMA-PET imaging
Copyright © 2020 Elsevier B.V. All rights reserved..
BACKGROUND: PSMA-PET1 has shown good concordance with histology, but there is a need to investigate the ability of PSMA-PET to delineate DIL2 boundaries for guided biopsy and focal therapy planning.
OBJECTIVE: To determine threshold and margin combinations that satisfy the following criteria: ≥95% sensitivity with max specificity and ≥95% specificity with max sensitivity.
DESIGN, SETTING AND PARTICIPANTS: We registered pathologist-annotated whole-mount mid-gland prostatectomy histology sections cut in 4.4 mm intervals from 12 patients to pre-surgical PSMA-PET/MRI by mapping histology to ex-vivo imaging to in-vivo imaging. We generated PET-derived tumor volumes using boundaries defined by thresholded PET volumes from 1-100% of SUV3max in 1% intervals. At each interval, we applied margins of 0-30 voxels in one voxel increments, giving 3000 volumes/patient.
OUTCOME MEASUREMENTS: Mean and standard deviation of sensitivity and specificity for cancer detection within the 2D oblique histologic planes that intersected with the 3D PET volume for each patient.
RESULTS AND LIMITATIONS: A threshold of 67% SUV max with an 8.4 mm margin achieved a (mean ± std.) sensitivity of 95.0 ± 7.8% and specificity of 76.4 ± 14.7%. A threshold of 81% SUV max with a 5.1 mm margin achieved sensitivity of 65.1 ± 28.4% and specificity of 95.1 ± 5.2%.
CONCLUSIONS: Preliminary evidence of thresholding and margin expansion of PSMA-PET images targeted at DILs validated with histopathology demonstrated excellent mean sensitivity and specificity in the setting of focal therapy/boosting and guided biopsy. These parameters can be used in a larger validation study supporting clinical translation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:152 |
|---|---|
| Enthalten in: |
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology - 152(2020) vom: 01. Nov., Seite 34-41 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alfano, Ryan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dominant intraprostatic lesion |
|---|
| Anmerkungen: |
Date Completed 14.04.2021 Date Revised 14.04.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.radonc.2020.08.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314012281 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314012281 | ||
| 003 | DE-627 | ||
| 005 | 20231225151819.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.radonc.2020.08.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1046.xml |
| 035 | |a (DE-627)NLM314012281 | ||
| 035 | |a (NLM)32827589 | ||
| 035 | |a (PII)S0167-8140(20)30726-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alfano, Ryan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Histologic validation of auto-contoured dominant intraprostatic lesions on [18F] DCFPyL PSMA-PET imaging |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.04.2021 | ||
| 500 | |a Date Revised 14.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: PSMA-PET1 has shown good concordance with histology, but there is a need to investigate the ability of PSMA-PET to delineate DIL2 boundaries for guided biopsy and focal therapy planning | ||
| 520 | |a OBJECTIVE: To determine threshold and margin combinations that satisfy the following criteria: ≥95% sensitivity with max specificity and ≥95% specificity with max sensitivity | ||
| 520 | |a DESIGN, SETTING AND PARTICIPANTS: We registered pathologist-annotated whole-mount mid-gland prostatectomy histology sections cut in 4.4 mm intervals from 12 patients to pre-surgical PSMA-PET/MRI by mapping histology to ex-vivo imaging to in-vivo imaging. We generated PET-derived tumor volumes using boundaries defined by thresholded PET volumes from 1-100% of SUV3max in 1% intervals. At each interval, we applied margins of 0-30 voxels in one voxel increments, giving 3000 volumes/patient | ||
| 520 | |a OUTCOME MEASUREMENTS: Mean and standard deviation of sensitivity and specificity for cancer detection within the 2D oblique histologic planes that intersected with the 3D PET volume for each patient | ||
| 520 | |a RESULTS AND LIMITATIONS: A threshold of 67% SUV max with an 8.4 mm margin achieved a (mean ± std.) sensitivity of 95.0 ± 7.8% and specificity of 76.4 ± 14.7%. A threshold of 81% SUV max with a 5.1 mm margin achieved sensitivity of 65.1 ± 28.4% and specificity of 95.1 ± 5.2% | ||
| 520 | |a CONCLUSIONS: Preliminary evidence of thresholding and margin expansion of PSMA-PET images targeted at DILs validated with histopathology demonstrated excellent mean sensitivity and specificity in the setting of focal therapy/boosting and guided biopsy. These parameters can be used in a larger validation study supporting clinical translation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Dominant intraprostatic lesion | |
| 650 | 4 | |a Focal boosting | |
| 650 | 4 | |a Guided biopsy | |
| 650 | 4 | |a Magnetic resonance imaging | |
| 650 | 4 | |a Positron-emission tomography | |
| 650 | 4 | |a Prostate cancer | |
| 700 | 1 | |a Bauman, Glenn S |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Thiessen, Jonathan D |e verfasserin |4 aut | |
| 700 | 1 | |a Rachinsky, Irina |e verfasserin |4 aut | |
| 700 | 1 | |a Pavlosky, William |e verfasserin |4 aut | |
| 700 | 1 | |a Butler, John |e verfasserin |4 aut | |
| 700 | 1 | |a Gaed, Mena |e verfasserin |4 aut | |
| 700 | 1 | |a Moussa, Madeleine |e verfasserin |4 aut | |
| 700 | 1 | |a Gomez, Jose A |e verfasserin |4 aut | |
| 700 | 1 | |a Chin, Joseph L |e verfasserin |4 aut | |
| 700 | 1 | |a Pautler, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Ward, Aaron D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology |d 1993 |g 152(2020) vom: 01. Nov., Seite 34-41 |w (DE-627)NLM012598305 |x 1879-0887 |7 nnns |
| 773 | 1 | 8 | |g volume:152 |g year:2020 |g day:01 |g month:11 |g pages:34-41 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.radonc.2020.08.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 152 |j 2020 |b 01 |c 11 |h 34-41 | ||